Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16998407 | 0.89 | INMT (0.33) | CYP3A4CYP2D6CYP2C19MEN1ALDH1A1 | |
| SCHEMBL20970108 | 0.76 | GPBAR1 (0.32) | GRM5 | |
| SCHEMBL14279925 | 0.76 | TRPV1 (0.35) | — | |
| SCHEMBL14468626 | 0.76 | GPBAR1 (0.32) | GRM5PIK3CAMTOR | |
| SCHEMBL18743042 | 0.74 | GRM5 (0.42) | GRM5MEN1KMT2A | |
| SCHEMBL11916077 | 0.73 | CYP3A4 (0.38) | CYP3A4CYP2D6CYP2C19GRM5MEN1 | |
| SCHEMBL23385241 | 0.71 | HSP90AA1 (0.34) | GRM5 | |
| SCHEMBL24317897 | 0.69 | HRH3 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL24315795 | 0.69 | JAK2 (0.34) | — | |
| SCHEMBL25045611 | 0.69 | GRM5 (0.30) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021038095-A1 | PEPTIDES AND METHODS FOR THE CARBON-CARBON BOND FORMATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-03-04 | — | — | WO | disclosed |
| EP-3786290-A1 | PEPTIDES AND METHODS FOR THE CARBON-CARBON BOND FORMATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-9567345-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-9434763-B2 | Derivatives of pyridinone as inhibitors for tissue transglutaminase | ZEDIRA GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9434763-B2 | Derivatives of pyridinone as inhibitors for tissue transglutaminase | ZEDIRA GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| EP-2820020-B1 | PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2423208-A1 | Pharmaceutically active compounds as Axl inhibitors | Lead Discovery Center GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| EP-1918286-B1 | Thiazolhydrazides for treatment of neurodegenerative diseases | MAX PLANCK GESELLSCHAFT (DE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2210881-A1 | Derivatives of syringolin A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081731-A2 | DERIVATIVES OF SYRINGOLIN A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V (DE) | 2010-07-22 | — | — | WO | disclosed |
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | TECHNISCHE UNIVERSITAT DARMSTADT (DE) | 2010-06-17 | — | — | US | disclosed |
| WO-2009068322-A1 | SELECTIVE INHIBITION OF POLO-LIKE KINASE 1 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENS CHAFTEN E.V. (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-2065039-A1 | Selective inhibition of Polo-like kinase 1 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008052804-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918286-A1 | Thiazolhydrazides for treatment of neurodegenerative diseases | MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | CYP3A4 2610/4885CYP2D6 3171/4885CYP2C19 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.